HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sabinsa’s Curcumin Complex Reduces Inflammation In Traumatic Brain Injury Patients

Executive Summary

Iranian researchers found using 500 mg curcumin complex daily for seven days reduced levels of leptin, which can promote inflammatory response, in patients with traumatic brain injury. In study published in Phytotherapy Research, 28 subjects had an overall 47.1% reduction in leptin.

You may also be interested in...



Sabinsa Adds Patents To Thwart ‘Low Quality Copycats,’ Launches Liver Health Supplement

Two patents in Mexico in past month for and three in Canada for compositions intended to slow inflammation and to strengthen hair growth.. It also recently launched LivLonga, a patented formulation to benefit liver health.

Pandemic-Driven Trends Show Strong Immunity Supplement Future, Elderberry A Current 'Darling'

VMS, homeopathic and other natural producs firms couldn't plan for spike in demand from coronavirus 2019, but the pandemic provides information to continue riding heightened consumer interest to higher ongoing sales, researchers said in recent Council for Responsible Nutrition webinar.

AHPA Members Report Problems In Raw Material, Other Supplies In Pandemic Survey For USDA

Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel